SCHEMBL17493530

SCHEMBL17493530

COc1cc(-c2ccc(O)c(F)c2)ccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.47
DHODH Q02127 1/20 0.47
CYP17A1 P05093 3/20 0.46
CYP3A4 P08684 2/20 0.46
CYP19A1 P11511 2/20 0.46
CYP11B1 P15538 2/20 0.46
CYP11B2 P19099 2/20 0.46
PDE3B Q13370 1/20 0.44
PDE3A Q14432 1/20 0.44
RPS6KA3 P51812 1/20 0.44
ESR1 P03372 5/20 0.44
ESR2 Q92731 5/20 0.44
HSD17B1 P14061 2/20 0.44
HSD17B2 P37059 2/20 0.44
MAPK13 O15264 1/20 0.43
MAPK12 P53778 1/20 0.43
MAPK11 Q15759 1/20 0.43
MAPK14 Q16539 1/20 0.43
MGLL Q99685 1/20 0.43
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24196194 0.81 KIT (0.47) NR4A2DHODHCYP3A4PDE3BPDE3A
SCHEMBL30626327 0.80 LOX (0.55) CYP19A1SLC13A5
SCHEMBL16116782 0.80 LOX (0.55) CYP19A1SLC13A5
SCHEMBL22283952 0.80 HSD17B1 (0.49) ESR1ESR2HSD17B1HSD17B2SLC13A5
SCHEMBL22797385 0.79 S1PR1 (0.49) SLC13A5
SCHEMBL17503147 0.78 ERN1 (0.51) NR4A2DHODHPDE3BPDE3ARPS6KA3
SCHEMBL22313787 0.78 SLC13A5 (0.45) NR4A2DHODHCYP3A4MAPK13MAPK12
SCHEMBL29431740 0.76 NR4A2 (0.44) NR4A2DHODHHSD17B1HSD17B2MAPK13
SCHEMBL20447052 0.76 AAK1 (0.56) NR4A2DHODHCYP3A4PDE3BPDE3A
SCHEMBL25105961 0.76 PDE3B (0.44) NR4A2DHODHCYP3A4PDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3177282-B1 ANTIDIABETIC BICYCLIC COMPOUNDS MERCK SHARP & DOHME (US) 2021-10-06 EP disclosed
US-10662171-B2 Antidiabetic bicyclic compounds MERCK SHARP & DOHME CORP. (US) 2020-05-26 US disclosed
US-20170217920-A1 ANTIDIABETIC BICYCLIC COMPOUNDS MERCK SHARP & DOHME LLC 2017-08-03 US disclosed
EP-3177282-A1 ANTIDIABETIC BICYCLIC COMPOUNDS Merck Sharp & Dohme Corp. (US) 2017-06-14 EP disclosed
WO-2016022448-A1 ANTIDIABETIC BICYCLIC COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2016-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10662171-B2 Antidiabetic bicyclic compounds GPR119, GPR65, GLP1R NR4A2 69/4885DHODH 3564/4885CYP17A1 1301/4885
US-20170217920-A1 ANTIDIABETIC BICYCLIC COMPOUNDS GPR119, GPR65, GLP1R NR4A2 69/4885DHODH 3564/4885CYP17A1 1301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.